14. An isolated cell expressing an antibody or antigen-binding fragment according to any one of the claims 1 to 10 and /or comprising a nucleic acid according to claim 12 or a vector according to claim 13.

15. An isolated cell according to claim 14, wherein said cell is a prokaryotic or an eukaryotic cell.

16. A method of producing an antibody or antigen-binding fragment according to any one of the claims 1 – 10 comprising culturing of a cell according to claim 15 and purification of the antibody or antigen-binding fragment.

17. An antibody or antigen-binding fragment according to claims 1 – 10 or an antibody-drug conjugate according to claim 11 for use as a medicament.

18. An antibody or antigen antigen-binding fragment according to claims 1 – 10 for use as a diagnostic agent.

19. An antibody or antigen-binding fragment according to claims 1 – 10 or an antibody-drug conjugate according to claim 11 for use as a medicament for the treatment of cancer.

20. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claims 1 – 10 or an antibody-drug conjugate according to claim 11.

21. A combination of a pharmaceutical composition according to claim 20 and one or more therapeutically active compounds.

22. A method for treating a disorder or condition associated with the undesired presence of TWEAKR, comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition according to claim 20 or a combination according to claim 21.

14. An isolated cell expressing an antibody or antigen-binding fragment according to any one of the claims 1 to 10 and /or comprising a nucleic acid according to claim 12 or a vector according to claim 13.

15. An isolated cell according to claim 14, wherein said cell is a prokaryotic or an eukaryotic cell.

16. A method of producing an antibody or antigen-binding fragment according to any one of the claims 1 – 10 comprising culturing of a cell according to claim 15 and purification of the antibody or antigen-binding fragment.

17. An antibody or antigen-binding fragment according to claims 1 – 10 or an antibody-drug conjugate according to claim 11 for use as a medicament.

18. An antibody or antigen-binding fragment according to claims 1 – 10 for use as a diagnostic agent.

19. An antibody or antigen-binding fragment according to claims 1 – 10 or an antibody-drug conjugate according to claim 11 for use as a medicament for the treatment of cancer.

20. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claims 1 – 10 or an antibody-drug conjugate according to claim 11.

21. A combination of a pharmaceutical composition according to claim 20 and one or more therapeutically active compounds.

22. The pharmaceutical composition according to claim 20 or the combination according to claim 21 for use in the treatment of a disorder or condition associated with the undesired presence of TWEAKR.

23. The use of the pharmaceutical composition according to claim 20 or the combination according to claim 21 in the manufacture of a medicament for the treatment of a disorder or condition associated with the undesired presence of TWEAKR.